DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Dopaminergic Modulation of Cognition and Psychomotor Function

Information source: Maastricht University Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Dopamine Activity; Episodic Memory Consolidation; Response Preparation

Intervention: Methylphenidate 40 mg (Drug); Levodopa/carbidopa 125 mg (Drug); Domperidon 10 mg (Drug)

Phase: N/A

Status: Completed

Sponsored by: Maastricht University Medical Center

Official(s) and/or principal investigator(s):
Eric Vuurman, Dr., Principal Investigator, Affiliation: Dept Neuropsychology and Psychopharmacology, Maastricht University

Summary

A recent study at our lab showed increased episodic memory consolidation and response readiness after treatment with methylphenidate in healthy volunteers. The investigators seek to replicate and extend these findings. Furthermore the pharmacological specificity of these effects will be studied. Since methylphenidate has an effect on two neurotransmitters, dopamine and noradrenaline, either could be responsible for the observed effects. In order to explore the dopaminergic contribution to this effect, the study proposed here includes not only methylphenidate but also levodopa/carbidopa, which only affects dopamine and not noradrenaline. In this study, 20 healthy males and females between 18 and 45 years of age will participate. They will be recruited via advertisements at Maastricht University and in local newspapers. Participants will be treated once with methylphenidate, once with levodopa/carbidopa and once with placebo. All medications will be administered orally with a capsule. It is hypothesized that methylphenidate and levodopa/carbidopa will both enhance episodic memory consolidation and improve response readiness

Clinical Details

Official title: Dopaminergic Modulation of Cognition and Psychomotor Function

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Primary outcome: Behavioral score on the Word learning test

Secondary outcome:

CNV amplitude

Reaction time on the CNV

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female

- 18 to 45 years of age

- Healthy (i. e. absence of all exclusion criteria), normal static binocular acuity

(corrected or uncorrected),

- Body mass index between 18. 5 and 30

- Willingness to sign an informed consent.

Exclusion Criteria:

- history of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal,

haematological or psychiatric illness.

- history of depression, bipolar disorder, anxiety disorder, panic disorder, psychosis,

or attention deficit hyperactivity disorder will be excluded from participation.

- first-degree relative with a psychiatric disorder or a history with a psychiatric

disorder

- excessive drinking (>20 glasses of alcohol containing beverages a week

- pregnancy or lactation

- use of medication other than oral contraceptives

- use of recreational drugs from 2 weeks before until the end of the experiment

- any condition in which gastrointestinal motility might carry any risk

- any sensory or motor deficits which could reasonably be expected to affect test

performance

Locations and Contacts

Maastricht University, Maastricht, Limburg 6200, Netherlands
Additional Information

Starting date: November 2010
Last updated: October 24, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017